Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Mechanistic regulation of HLA binding receptors during human natural killer cell development

Award Number: R01AI198432
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/22/2026
PERIOD OF PERFORMANCE END DATE: 05/31/2031

Group Awards By:

View Award Description

Mechanistic regulation of HLA binding receptors during human natural killer cell development - PROJECT SUMMARY Natural killer (NK) cells are innate lymphocytes that regulate multiple components of the innate and adaptive immune systems and have direct cytotoxic function against pathogen-infected cells and cancer cells. NK cells complement T cell immune surveillance and can mediate an important graft-versus-leukemia effect following allogeneic hematopoietic stem cell transplantation for acute leukemia. During pregnancy, maternal NK cells are unique mediators in the carefully orchestrated processes of implantation, placentation, and fetal growth; and they are also poised to rapidly respond to infection. In these and other settings, NK cells rely on their expression of inhibitory and activating cell surface receptors to sense their environment and communicate with other cells. Killer immunoglobulin-like receptors (KIRs) comprise a large family of receptors that bind human leukocyte antigen (HLA) molecules and enable NK cells to distinguish healthy from diseased cells. Despite their central importance to NK cell function, it is not yet known how KIR expression is regulated during NK cell development. For over 20 years we have worked to identify and characterize NK cell developmental intermediates (NKDIs) in human tissues and to determine how their differentiation and maturation are regulated. Although KIR acquisition occurs during late stages of NK cell maturation, we now have preliminary data to indicate that prior to this developmental window, early stage NKDIs require a conducive microenvironment to become primed for subsequent development into KIR+ NK cells. Moreover, our findings have uncovered a paradoxical inhibitory role of the NK cell growth factor, interleukin (IL)-15, during the priming phase of human NK cell development, thus challenging current dogma and raising important clinical implications for NK cell mediated therapies. The central goal of this proposal is to elucidate the mechanisms regulating KIR acquisition during human NK cell development. Our specific aims are: 1) To determine how the microenvironment regulates NKDI priming for KIR acquisition; and 2) To elucidate cell intrinsic mechanisms of NKDI priming and its suppression by IL-15. We hypothesize that specific hematopoietic helper cells support NKDI priming by triggering activating receptors through a critical developmental synapse, in turn leading to MEK/ERK/AP-1 signaling and subsequent induction of sense transcription at KIR gene loci. Further, we hypothesize that these critical priming steps are abrogated in the setting of early-stage exposure to IL-15, at least in part through dysregulated STAT5- and mTOR-dependent sense and antisense expression at KIR promoters. In Aim 1 we propose a series of experiments to determine how soluble factors and cell-cell interactions in the microenvironment mediate NKDI priming. In Aim 2 we will investigate NKDI cell intrinsic mechanisms to determine how priming affects KIR promoter expression and how IL-15 subverts NK cell priming and subsequent KIR acquisition. Our overarching goal is to gain a comprehensive understanding of the processes that regulate KIR acquisition during human NK cell development to best understand how NK cell functions can be enhanced in the face of human disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $692,930 )
2026	2026	OHIO STATE UNIVERSITY, THE	1960 KENNY RD	COLUMBUS	OH	43210	FRANKLIN	USA	Allergy and Infectious Diseases Research	000	1	6/23/2026	NEW	$692,930
														Subtotal = $692,930

Grand Total All Awards = $692,930

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Mechanistic regulation of HLA binding receptors during human natural killer cell development

Award Number: R01AI198432

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/22/2026

PERIOD OF PERFORMANCE END DATE: 05/31/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer